RESUMEN
The visualization of regulatory networks is becoming increasingly important in order to understand molecular mechanisms and diseases. MicroRNAs (miRNAs) are small noncoding RNAs (ncRNAs) responsible of the post-transcriptional regulation of messenger RNAs (mRNAs) and other ncRNAs. MiRNAs are involved in numerous biological processes including development, cell proliferation, and apoptosis. They are also key molecules in major complex diseases such as cancer and cardiovascular diseases. A single miRNA can regulate many targets, making the analysis and visualization of these complex networks challenging. Here, we present standard and advanced visualization approaches to represent networks with a special focus on miRNA-target interactions.
Asunto(s)
Perfilación de la Expresión Génica/métodos , Redes Reguladoras de Genes , MicroARNs/genética , ARN Mensajero/genética , Programas Informáticos , Biología Computacional/métodos , Regulación de la Expresión Génica , Humanos , MicroARNs/metabolismo , ARN Mensajero/metabolismoRESUMEN
PURPOSE: Most chromosome abnormality patients require long-term clinical care. Awareness of mosaicism and comorbidities can potentially guide such health care. Here we present a population-wide analysis of direct and inverse comorbidities affecting patients with chromosome abnormalities. METHODS: We extracted direct and inverse comorbidities for the 11 most prevalent chromosome abnormalities from the Danish National Patient Registry (covering 6.9 million patients hospitalized between 1994 and 2015): trisomy 13, 18, and 21, Klinefelter (47,XXY), triple X, XYY, Turner (45,X), Wolf-Hirschhorn, Cri-du-chat, Angelman, and Fragile X syndromes (FXS). We also performed four sub-analyses for male/female Down syndrome (DS) and FXS and non-mosaic/mosaic DS and Turner syndrome. RESULTS: Our data cover 9,003 patients diagnosed with at least one chromosome abnormality. Each abnormality showed a unique comorbidity signature, but clustering of their profiles underlined common risk profiles for chromosome abnormalities with similar genetic backgrounds. We found that DS had a decreased risk for three inverse cancer comorbidities (lung, breast, and skin) and that male FXS and non-mosaic patients have a much more severe phenotype than female FXS and mosaic patients, respectively. CONCLUSION: Our study underlines the importance of considering mosaicism, sex, and the associated comorbidity profiles of chromosome abnormalities to guide long-term health care of affected patients.
Asunto(s)
Trastornos de los Cromosomas/epidemiología , Comorbilidad , Aberraciones Cromosómicas , Dinamarca/epidemiología , Femenino , Humanos , Cariotipificación , Masculino , Mosaicismo , Sistema de Registros , Aberraciones Cromosómicas Sexuales , TrisomíaRESUMEN
Methods that integrate molecular network information and tumor genome data could complement gene-based statistical tests to identify likely new cancer genes; but such approaches are challenging to validate at scale, and their predictive value remains unclear. We developed a robust statistic (NetSig) that integrates protein interaction networks with data from 4,742 tumor exomes. NetSig can accurately classify known driver genes in 60% of tested tumor types and predicts 62 new driver candidates. Using a quantitative experimental framework to determine in vivo tumorigenic potential in mice, we found that NetSig candidates induce tumors at rates that are comparable to those of known oncogenes and are ten-fold higher than those of random genes. By reanalyzing nine tumor-inducing NetSig candidates in 242 patients with oncogene-negative lung adenocarcinomas, we find that two (AKT2 and TFDP2) are significantly amplified. Our study presents a scalable integrated computational and experimental workflow to expand discovery from cancer genomes.
Asunto(s)
Carcinogénesis/genética , Biología Computacional/métodos , Regulación Neoplásica de la Expresión Génica , Redes Reguladoras de Genes , Proteínas de Neoplasias/genética , Neoplasias/genética , Humanos , MutaciónRESUMEN
The co-occurrence of diseases can inform the underlying network biology of shared and multifunctional genes and pathways. In addition, comorbidities help to elucidate the effects of external exposures, such as diet, lifestyle and patient care. With worldwide health transaction data now often being collected electronically, disease co-occurrences are starting to be quantitatively characterized. Linking network dynamics to the real-life, non-ideal patient in whom diseases co-occur and interact provides a valuable basis for generating hypotheses on molecular disease mechanisms, and provides knowledge that can facilitate drug repurposing and the development of targeted therapeutic strategies.
